Observational studyInvestigative and clinical urology2021
Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study.
Observational study in Investigative and clinical urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of repeated prostate-specific antigen testing on management patterns and personal healthcare spending for prostate cancer: A population-based study National Health Insurance data for 166,848 patients in South Korea from 2010 to 2020.Investigative and clinical urology · 2026Article
- Projection of Cancer Incidence and Mortality From 2020 to 2035 in the Korean Population Aged 20 Years and Older.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2022Article
- Should Contemporary Western Guidelines Based on Studies Conducted in the 2000s Be Adopted for the Prostate-Specific Antigen Screening Policy for Asian Men in the 2020s?The world journal of men's health · 2022Review
- The national-wide incidence of prostate-specific antigen testing trend for a decade in Korea by age group.Investigative and clinical urology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the real-world prevalence of repeated prostate-specific antigen (PSA) screening in Korea and its influence on the treatment pattern of the prostate cancer (PCa) over the last decade, during which PCa has become the 3rd most popular male cancer and PSA test has gained minimal social interest. MATERIALS AND
methodsFrom Korean National Health Insurance Service data, men with newly diagnosed PCa from 2008 through 2016 were identified, then the treatment modalities between the repeated PSA screening (defined as at least three PSA tests during minimal 2 years before registration) and non-screening groups (when the first PSA test was performed within 3 months before registration) were compared.
resultsAmong 73,280 men with PCa, only 27.7% met the criteria for screening. In contrast with the continuous increase in the screening population from 334 men in 2008 to 5,049 men in 2016, the non-screening population remained low at 1,543 men in 2008 and 1,819 men in 2016 (p<0.001). During these periods, more patients underwent local therapy (prostatectomy or radiation) in the screening population compared to their non-screened counterparts (59.8% vs. 46.7%, p<0.001), and fewer patients underwent systemic therapy (chemotherapy or hormone) (40.2% vs. 53.3%, p<0.001). Multivariate analysis adjusting other variables demonstrated 2-fold higher mortality in the non-screening population (hazard ratio=2.050, p<0.0001).
conclusionsAmong the patients newly diagnosed with PCa, only about a quarter received repeated PSA screening. However, these patients showed a higher probability of local treatment than the systemic one in comparison with non-screened counterparts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.